China approves brain chip to treat paralysis — a world first
Summary
China’s National Medical Products Administration has authorised NEO, a brain–computer interface (BCI) developed by Neuracle Medical Technology in Shanghai, for wider clinical use in people with severe paralysis caused by high cervical spinal-cord injury. The coin-sized device is embedded in the skull, with eight electrodes over one hemisphere that record signals when the user imagines moving their opposite hand. Those signals are decoded by a computer and used to operate a soft robotic glove, enabling grasping and simple daily tasks. The approval follows up to 18 months of data from clinical trials and represents the first regulatory clearance of a BCI for routine use beyond trials.
Key Points
- NEO is the first brain implant approved anywhere for wider clinical use to help people with severe paralysis regain hand function.
- The device sits in the skull with eight surface electrodes, recording imagined-movement signals that are decoded to control a soft robotic glove.
- Approvals cover adults aged 18–60 with tetraplegia from neck-level spinal-cord injuries.
- Clinical data include up to 18 months of follow-up; 32 people have received the implant and could perform grasping with the glove.
- NEO is semi‑invasive (embedded in the skull) and less invasive than some alternatives that penetrate brain tissue, which may have helped its faster approval.
- Researchers caution the trial cohorts are small and long-term results and wider effectiveness still require careful reporting and peer review.
- The approval is a milestone for the BCI field and fits China’s broader strategy to develop a neurotech industry.
Author style
Punchy: This is a major milestone in neurotechnology — a rare regulatory win for a BCI that actually moves beyond trials. If you follow neurotech, medtech regulation or disability tech, the full details are worth your time because this changes the practical landscape for implantable BCIs.
Why should I read this?
Short and blunt: if you care about devices that could restore movement, regulatory shifts in medtech, or where neurotech is heading (especially with China pushing hard), read this. It’s the first time a BCI has been cleared for wider use — that matters.
Context and relevance
This approval is significant for several reasons: it is the first time a BCI has gained regulatory clearance for broader clinical use, it demonstrates a semi‑invasive approach that may reduce risk compared with fully penetrating implants, and it underscores China’s ambitions to build a neurotechnology industry. The development sits alongside other long‑running BCI efforts globally (for speech, mobility and prosthetic control) and will prompt close scrutiny of safety, durability and real-world benefits as larger cohorts and peer‑reviewed results emerge.